Revenue
2019
2020
2021
2022
2023
2024
2025
Abionyx Pharma (ABNX)
Price€1.90Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | €4.1M | €4.6M | €4.6M | €5.3M | €675,000 | €0 | €0 |
| Gross profit | €534,000 | €844,000 | €618,000 | €636,000 | €259,000 | €0 | €0 |
| Gross margin | 13.14% | 18.55% | 13.32% | 12.11% | 38.37% | — | — |
| Research & development | €1.5M | €1.9M | €1.5M | €1.1M | €3.8M | €1.7M | €744,000 |
| Operating expenses | €6.1M | €5.3M | €4.0M | €4.7M | €6.2M | €3.0M | €2.5M |
| Operating income | −€5.5M | −€4.5M | −€3.4M | −€4.1M | −€6.0M | −€3.0M | −€2.5M |
| Operating margin | −136.30% | −98.11% | −73.53% | −78.24% | −881.78% | — | — |
| EBITDA | −€5.4M | −€4.3M | −€3.3M | −€4.0M | — | — | — |
| EBITDA margin | −133.20% | −95.14% | −70.24% | −75.67% | — | — | — |
| Net income | −€5.5M | −€4.4M | −€3.5M | −€4.2M | −€5.8M | −€1.9M | €1.8M |
| Net profit margin | −136.60% | −96.26% | −75.82% | −80.08% | −862.52% | — | — |
| Basic EPSper basic share | -€0.16 | -€0.13 | -€0.12 | -€0.15 | -€0.23 | -€0.08 | €0.09 |
| Diluted EPSper diluted share | -€0.16 | -€0.13 | -€0.12 | -€0.15 | -€0.23 | -€0.08 | €0.09 |